Trial Profile
A PHASE III, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 14 Nov 2017 New trial record